Mortensen J, Groth S, Lange P, Hermansen F
Department of Clinical Physiology and Nuclear Medicine, Copenhagen, Denmark.
Thorax. 1991 Nov;46(11):817-23. doi: 10.1136/thx.46.11.817.
beta Agonists have been shown to increase mucociliary clearance in some studies but not all. Whether the formulation of beta agonists affects mucociliary clearance is not known but may be important as the use of dry powder inhalers increases.
The effect of different methods of administration of inhaled terbutaline on mucociliary clearance and forced expiratory volume in one second (FEV1) was assessed in 10 patients with asthma and 10 healthy subjects. Terbutaline (1 mg) was administered through a metered dose inhaler with a spacer (Nebuhaler) or a dry powder inhaler (Turbuhaler), or both treatments were given, in a four way double blind, double dummy trial. Mucociliary clearance was measured by bronchoscintigraphy.
Clearance of radioactivity from the lobar bronchi increased in the asthmatic patients by a median of 32% after terbutaline was given by metered dose inhaler and 55% after a combined dose of 2 mg from both inhalers (1 mg from each) compared with placebo but by only 9% after 1 mg of terbutaline was given by a dry powder inhaler. In the healthy subjects mucociliary clearance increased by 51% when terbutaline was given by a dry powder inhaler, by 66% when given by a metered dose inhaler, and by 66% when given by both inhalers combined. The effect of terbutaline on FEV1 was the same with each of the inhalers.
Despite similar changes in FEV1 with the two formulations terbutaline increased mucociliary clearance significantly in asthmatic and healthy subjects when inhaled from a metered dose inhaler whereas when it was inhaled from a dry powder inhaler its effect was significant only in healthy subjects. The reason for the difference in asthmatic subjects is unclear, but may be associated with differences in the deposition of terbutaline.
一些研究表明β受体激动剂可增加黏液纤毛清除功能,但并非所有研究均如此。β受体激动剂的剂型是否会影响黏液纤毛清除功能尚不清楚,但随着干粉吸入器使用的增加,这一点可能很重要。
在10例哮喘患者和10名健康受试者中评估了吸入特布他林的不同给药方法对黏液纤毛清除功能和一秒用力呼气容积(FEV1)的影响。在一项四交叉双盲、双模拟试验中,通过定量气雾剂加储雾罐(Nebuhaler)或干粉吸入器(Turbuhaler)给予特布他林(1毫克),或两种治疗方法均采用。通过支气管闪烁显像法测量黏液纤毛清除功能。
与安慰剂相比,哮喘患者经定量气雾剂给药后叶支气管放射性清除率中位数增加32%,两种吸入器联合给予2毫克(每种1毫克)后增加55%,但经干粉吸入器给予1毫克特布他林后仅增加9%。在健康受试者中,干粉吸入器给予特布他林时黏液纤毛清除率增加51%,定量气雾剂给药时增加66%,两种吸入器联合给药时增加66%。特布他林对FEV1的影响在每种吸入器中相同。
尽管两种剂型的特布他林对FEV1的影响相似,但从定量气雾剂吸入时,特布他林可显著增加哮喘患者和健康受试者的黏液纤毛清除功能,而从干粉吸入器吸入时,其作用仅在健康受试者中显著。哮喘患者出现这种差异的原因尚不清楚,但可能与特布他林的沉积差异有关。